This episode from WOWTALE presents an interview with SimfliBIO, a Korean startup specializing in liquid biopsy for cancer diagnostics. The article highlights SimfliBIO's novel technology, which boasts significantly higher sensitivity in detecting circulating tumor DNA (ctDNA) compared to existing methods like Next Generation Sequencing (NGS) and PCR. This advanced approach allows for earlier and more precise cancer diagnosis, companion diagnostics (guiding targeted therapies), and minimal residual disease (MRD) detection. The company aims to challenge global market leaders through clinical trials and eventually expand into various cancer screening and diagnostic applications.